Graça M Dores1,2, Rochelle E Curtis1, Nicole H Dalal1,3, Martha S Linet1, Lindsay M Morton1. 1. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD. 2. US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, Silver Spring, MD. 3. Duke University School of Medicine, Durham, NC.
Abstract
PURPOSE: Mortality for patients with classical Hodgkin lymphoma (cHL) treated during an era characterized in the United States by widespread use of doxorubicin, bleomycin, vinblastine, and dacarbazine and diminishing use of radiotherapy is not well understood. PATIENTS AND METHODS: We identified 20,007 individuals diagnosed with stage I/II (early) or III/IV (advanced) cHL between age 20 and 74 years treated with initial chemotherapy in US population-based cancer registries during 2000-2015 (follow-up through 2016). We used standardized mortality ratios (SMRs) to compare cause-specific relative mortality risk following cHL to that expected in the general population and estimated excess absolute risks (EARs; per 10,000 patient-years) to quantify disease-specific death burden. RESULTS: We identified 3,380 deaths in the cHL cohort, including 1,321 (39%) not attributed to lymphoma. Overall, noncancer SMRs were increased 2.4-fold (95% CI, 2.2 to 2.6; observed, 559; EAR, 61.6) and 1.6-fold (95% CI, 1.4 to 1.7; observed, 473; EAR, 18.2) for advanced- and early-stage cHL, respectively, compared with the general US population. SMRs and EARs differed substantially by cause of death and cHL stage. Among the highest EARs for noncancer causes of death were those for heart disease (EAR, 15.1; SMR, 2.1), infections (EAR, 10.6; SMR, 3.9), interstitial lung disease (ILD; EAR, 9.7; SMR, 22.1), and adverse events (AEs) related to medications/drugs (EAR, 7.4; SMR, 5.0) after advanced-stage cHL and heart disease (EAR, 6.6; SMR, 1.7), ILD (EAR, 3.7; SMR, 13.1), and infections (EAR, 3.1; SMR, 2.2) after early-stage cHL. Strikingly elevated SMRs for ILD, infections, and AEs were observed < 1 year after cHL. Individuals age 60-74 years with advanced-stage cHL experienced a disproportionate excess of deaths as a result of heart disease, ILD, infections, AEs, and solid tumors. CONCLUSION: Despite evolving cHL treatment approaches, patients continue to face increased nonlymphoma mortality risks from multiple, potentially preventable causes. Surveillance, early interventions, and cHL treatment refinements may favorably affect patient longevity, particularly among high-risk subgroups.
PURPOSE:Mortality for patients with classical Hodgkin lymphoma (cHL) treated during an era characterized in the United States by widespread use of doxorubicin, bleomycin, vinblastine, and dacarbazine and diminishing use of radiotherapy is not well understood. PATIENTS AND METHODS: We identified 20,007 individuals diagnosed with stage I/II (early) or III/IV (advanced) cHL between age 20 and 74 years treated with initial chemotherapy in US population-based cancer registries during 2000-2015 (follow-up through 2016). We used standardized mortality ratios (SMRs) to compare cause-specific relative mortality risk following cHL to that expected in the general population and estimated excess absolute risks (EARs; per 10,000 patient-years) to quantify disease-specific death burden. RESULTS: We identified 3,380 deaths in the cHL cohort, including 1,321 (39%) not attributed to lymphoma. Overall, noncancer SMRs were increased 2.4-fold (95% CI, 2.2 to 2.6; observed, 559; EAR, 61.6) and 1.6-fold (95% CI, 1.4 to 1.7; observed, 473; EAR, 18.2) for advanced- and early-stage cHL, respectively, compared with the general US population. SMRs and EARs differed substantially by cause of death and cHL stage. Among the highest EARs for noncancer causes of death were those for heart disease (EAR, 15.1; SMR, 2.1), infections (EAR, 10.6; SMR, 3.9), interstitial lung disease (ILD; EAR, 9.7; SMR, 22.1), and adverse events (AEs) related to medications/drugs (EAR, 7.4; SMR, 5.0) after advanced-stage cHL and heart disease (EAR, 6.6; SMR, 1.7), ILD (EAR, 3.7; SMR, 13.1), and infections (EAR, 3.1; SMR, 2.2) after early-stage cHL. Strikingly elevated SMRs for ILD, infections, and AEs were observed < 1 year after cHL. Individuals age 60-74 years with advanced-stage cHL experienced a disproportionate excess of deaths as a result of heart disease, ILD, infections, AEs, and solid tumors. CONCLUSION: Despite evolving cHL treatment approaches, patients continue to face increased nonlymphoma mortality risks from multiple, potentially preventable causes. Surveillance, early interventions, and cHL treatment refinements may favorably affect patient longevity, particularly among high-risk subgroups.
Authors: Andrew M Evens; Irene Helenowski; Erika Ramsdale; Chadi Nabhan; Reem Karmali; Britt Hanson; Benjamin Parsons; Scott Smith; Annette Larsen; June M McKoy; Borko Jovanovic; Stephanie Gregory; Leo I Gordon; Sonali M Smith Journal: Blood Date: 2011-11-23 Impact factor: 22.113
Authors: Sten Myrehaug; Melania Pintilie; Lingsong Yun; Michael Crump; Richard W Tsang; Ralph M Meyer; Jonathan Sussman; Eric Yu; David C Hodgson Journal: Blood Date: 2010-07-01 Impact factor: 22.113
Authors: Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245
Authors: Andreina E Kero; Liisa S Järvelä; Mikko Arola; Nea Malila; Laura M Madanat-Harjuoja; Jaakko Matomäki; Päivi M Lähteenmäki Journal: Int J Cancer Date: 2014-08-22 Impact factor: 7.396
Authors: Anthony J Swerdlow; Craig D Higgins; Paul Smith; David Cunningham; Barry W Hancock; Alan Horwich; Peter J Hoskin; Andrew Lister; John A Radford; Ama Z S Rohatiner; David C Linch Journal: J Natl Cancer Inst Date: 2007-02-07 Impact factor: 13.506
Authors: Stephen J Proctor; Jennifer Wilkinson; Gail Jones; Gillian C Watson; Helen H Lucraft; Tryfonia Mainou-Fowler; Dominic Culligan; Michael J Galloway; Katrina M Wood; Richard J Q McNally; Peter W James; John R Goodlad Journal: Blood Date: 2012-05-10 Impact factor: 22.113
Authors: Alejandro A Gru; Carlos E Bacchi; Melissa Pulitzer; Govind Bhagat; Werner Kempf; Alistair Robson; Jose A Plaza; Laura Pincus; Shyam Raghavan; Mina Xu; Tiago Vencato da Silva; Andrea L Salavaggione; Antonio Subtil; Maxime Battistella Journal: J Cutan Pathol Date: 2021-07-05 Impact factor: 1.458
Authors: Georgios Ntentas; Katerina Dedeckova; Michal Andrlik; Marianne C Aznar; Rebecca Shakir; Johanna Ramroth; Rubina Begum; Jiří Kubeš; Sarah C Darby; N George Mikhaeel; David J Cutter Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-09 Impact factor: 7.038
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J Andrew Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-08 Impact factor: 4.254